You have 9 free searches left this month | to do more
Showing 1 - 25 of
615 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
Z
Recruiting
  • Castrate-Resistant Prostate Cancer
  • PD1-PSMA-CART cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University
2022-02-26
Feb 26, 2022
F
Recruiting
  • Lung Cancer
  • Microbiota Transplant plus anti PD1 therapy
  • anti PD1 therapy
  • Madrid, Spain
    Hospital Universitario Ramón y Cajal
2021-11-16
Nov 16, 2021
U
Active, not recruiting
  • Solid Tumor
  • Chicago, Illinois
    University of Chicago
2022-03-14
Mar 14, 2022
B
Recruiting
  • EBV Infection
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
2022-01-04
Jan 4, 2022
U
Recruiting
  • Leptomeningeal Disease
  • Nivolumab [Opdivo]
  • Freiburg, Germany
  • +4 more
2021-12-13
Dec 13, 2021
C
Recruiting
  • Cancer
  • Biological samples
  • Anti PD1/PDL1 treatment
  • Besancon, France
    University Hospital of Besançon
2021-07-30
Jul 30, 2021
C
Not yet recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm
  • Copper Cu 64-DOTA-pembrolizumab
  • +2 more
  • Duarte, California
    City of Hope Medical Center
2022-02-16
Feb 16, 2022
S
Recruiting
  • DMMR Colorectal Cancer
  • +2 more
  • PD-1 Antibody
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
2021-09-22
Sep 22, 2021
S
Recruiting
  • Intrahepatic Cholangiocarcinoma
  • +3 more
  • Neoadjuvant treatment
  • Shanghai, Shanghai, China
    Zhongshan hospital
2021-07-05
Jul 5, 2021
A
Recruiting
  • Chronic Pain
  • Tramadol Hydrochloride
  • Assiut, Egypt
    Assiut University
2021-01-13
Jan 13, 2021
S
Recruiting
  • Liver Cancer
  • +7 more
  • TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3
  • Guangzhou, China
    Second Affiliated Hospital of Guangzhou Medical University
2021-04-09
Apr 9, 2021
C
Recruiting
  • Hodgkin Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Salt Lake City, Utah
  • +1 more
2021-07-14
Jul 14, 2021
S
Active, not recruiting
  • Cholangiocarcinoma, Intrahepatic
  • combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)
  • Shanghai, Shanghai, China
    Zhongshan Hospital
2021-07-05
Jul 5, 2021
S
Recruiting
  • Diffuse Large B-cell Lymphoma
  • CD19-7×19 CAR-T plus PD1 monoclonal antibody
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
2020-06-26
Jun 26, 2020
S
Recruiting
  • PD1
  • Acute Myocardial Infarction
  • PD1+ T Cell Expression
  • Hangzhou, Zhejiang, China
    The Second Affiliated Hospital of Zhejiang University, School of
2022-02-22
Feb 22, 2022
Z
Unknown status
  • Biliary Tract Cancer
  • Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin
  • Gemcitabine Plus(+)Cisplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
2020-03-06
Mar 6, 2020
S
Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Gemox combimed PD1 antibody
  • Shanghai, Shanghai, China
    Zhongshan hospital
2021-07-07
Jul 7, 2021
A
Recruiting
  • Melanoma
  • Nantes, France
  • +2 more
2022-03-28
Mar 28, 2022
S
Recruiting
  • Cholangiocarcinoma, Intrahepatic
  • neoadjuvant treatment
  • Shanghai, Shanghai, China
    Zhongshan hospital
2020-08-07
Aug 7, 2020
M
Active, not recruiting
  • Advanced Malignant Neoplasm
  • +2 more
  • Laboratory Biomarker Analysis
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-09
Nov 9, 2021
N
Recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Singapore, Singapore
  • +1 more
2022-03-10
Mar 10, 2022